SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending due to a new COO hire from Shopify, sparking optimism for a turnaround and talk of a potential short squeeze. The community is actively discussing the stock's impressive gains, high short interest, and potential for further upside, while cautioning against FOMO. Some traders are pointing to a possible gamma squeeze, while others suggest an offering could be coming.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending following news of volume shipments of NVIDIA Blackwell Ultra solutions, sparking community discussion around the company's role in AI infrastructure.  Investors are weighing the potential for a gamma squeeze and debating the impact of the news amid existing short positions. The community is also discussing partnerships with companies like Oracle and Nokia.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss its AI strategy and potential impact on earnings, with the company set to report earnings. Community members are weighing the balance between new AI features and established competition, pondering whether a positive report can reverse the stock's recent struggles. Options traders anticipate significant movement, evidenced by elevated premiums.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RH is trending following its earnings report and subsequent mixed reactions from the community, including a V-shape bounce in after-hours trading. While some investors express concern over missed revenue estimates and lowered guidance, others see potential in the company's expansion into Europe and potential benefits from future interest rate cuts. Community members are actively discussing possible price movements, with both bullish and bearish sentiments influencing the conversation.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as the community discusses the potential for a short squeeze and buyout, fueled by increased volume and positive sentiment around their drug belapectin. Community members highlight the unmet need in late-stage cirrhosis and potential catalysts such as FDA feedback and partnership opportunities.  Recent discussions center around the significance of FDA accepting liver stiffness measurement as a surrogate endpoint.

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram is trending amidst mixed sentiment, with some community members calling it a Chinese scam while others point to its potential in AI and crypto. The stock's low float and recent financial reports, including a reported profit, are being discussed, with some anticipating a squeeze while others remain skeptical due to the company's history and perceived lack of transparency.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid reports of a potential takeover bid from Paramount Skydance, sparking significant community discussion. Investors are weighing the implications of a possible cash-heavy offer and speculating about potential bidding wars, takeover prices, and the strategic rationale behind the deal given WBD's restructuring plans and valuable content library. Overall, the community seems excited about the potential for a buyout.

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Addex Therapeutics Ltd - ADR

ADXN is trending due to a recent surge, fueled by community excitement around its potential as a low-float runner and a collaboration announcement, driving speculation of a continued breakout. Traders are actively discussing accumulation strategies, potential price targets, and the possibility of a short squeeze given the stock's limited public float. The community draws comparisons to other low-float stocks that have experienced significant gains, suggesting potential for substantial upward movement.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending amid discussions about its newly unveiled social platform and the introduction of short selling on its platform. The community is analyzing the potential impact of these developments on Robinhood's competitive position and user engagement, with some speculating about its effects on existing platforms like Stocktwits. Additionally, the stock's inclusion in the S&P 500 is adding to the conversation, with investors assessing its long-term growth prospects.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid a notable price increase, sparking discussions about potential breakouts and a continued rally toward higher price targets. Community members are debating whether this movement is fundamentally driven or fueled by hype and short squeezes, with some pointing to Elon Musk's influence and potential new ventures like Optimus robots. The overall sentiment is mixed, as some traders anticipate a pullback while others remain bullish, citing technical indicators and potential market catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of AbbVie Inc. (ABBV) hit a fresh record high on Thursday before paring back some of the gains, after the company said it does not expect any generic versions of its Rinvoq in the U.S. before April 2037.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001551152/000110465925089245/tm2525781d1_8k.htm">stated</a> in a filing that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of Rinvoq.In the <a href="https://stocktwits.com/news-articles/markets/equity/abbvie-ceo-sees-substantial-momentum-for-remaining-year-after-q2-earnings-beat/choL9iDR56t">second quarter</a>, Rinvoq was the second most revenue-generating drug from AbbVie’s portfolio after Skyrizi. Global Rinvoq net revenues were $2.028 billion in the three months, representing a year-over-year increase of approximately 42% on a reported basis. Rinvoq is used to treat adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, moderate to severe ulcerative colitis, and Crohn's disease, among other conditions, in the U.S. It is also approved for the treatment of children 12 years of age and older with moderate to severe eczema.<a href="https://stocktwits.com/symbol/ABBV">Shares of ABBV</a> hit a new record high of over $221 over the news, before paring back some gains. The stock traded 4% higher at the time of writing.On Stocktwits, retail sentiment around ABBV jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:619/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_2_09_47_PM_png_e76c7e9a5b.webp" alt="ABBV's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="619" height="65"><figcaption>ABBV's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user termed the settlement “pretty big news.”<stembedurl>https://stocktwits.com/Jblack500/message/628289494</stembedurl>Another user expressed optimism that the stock could reach as high as $250.<stembedurl>https://stocktwits.com/shoagh12/message/628310961</stembedurl>Wells Fargo believes AbbVie's U.S. intellectual property settlement with generic players for Rinvoq gives the company a "really long runway" for the product. The news is a "big win" given that consensus expectations called for a patent expiration in 2032, the analyst told investors in a research note. Wells Fargo keeps an ‘Overweight’ rating on AbbVie with a $240 price target, representing an upside of over 13% from Wednesday’s closing price.ABBV stock is up by 24% this year and by about 14% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/toyota-recalls-over-half-million-vehicles-in-us/chwNo3dRdvu">Toyota Recalls Over Half A Million Vehicles In The US</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Abbvie Pharma logo seen on screen in the background with pills and a medical vial with syringe, seen in this photo illustration, on 14 August 2023 in Brussels, Belgium. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

AbbVie Stock Touches Record High After Company Dismisses Generic Competition For Rinvoq Till 2037: Wells Fargo Terms It A ‘Big Win’

The company stated in a filing that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of Rinvoq.

Equity

The company stated in a filing that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of Rinvoq.


SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal

Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.

This 3 Stock Portfolio Provides Monthly Income

If investors select their dividend-paying stocks in a structured manner, they can create a portfolio that provides monthly paydays. 

AbbVie (ABBV) Stock Dips While Market Gains: Key Facts

AbbVie (ABBV) closed at $210 in the latest trading session, marking a -1.2% move from the prior day.

Investing in Oncology: 3 Cancer Stocks With Promising Pipelines

Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.

J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?

ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.

Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?

ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.

Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales 

Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with $OPEN stock after the major announcements last night?

Stocktwits

 stock after the major announcements last night?

Current Price	$220.22
Prev Close	$211.64
Open	$220.35
Dividend Yield	3.54%
50-Day Moving Average	$198.72
Beta	0.36
Avg. Volume	4.59M
PE Ratio	100.72

52-Week High	$218.66
52-Week Low	$163.81
Market Capitalization	$373.87B
EPS (Annual)	$2.39
Price to Book	-2,042.86
Revenue Per Employee	$1.02M
Enterprise Value/EBITDA	N/A

ABBV
Abbvie Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABBV News

ABBV Abbvie Inc